Document:

EX-4.3

 Exhibit 4.3 

THIS WARRANT (AND THE SECURITIES ISSUABLE HEREUNDER) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. 
  

			
	Warrant No.         		Dated as of             , 2010

 NUTANIX, INC. 

WARRANT TO PURCHASE SHARES OF CAPITAL STOCK 

THIS CERTIFIES that, for value received,
[                    ], its successors and permitted assigns (the “Holder”), is entitled, upon the terms and subject to the
conditions hereinafter set forth in this instrument (the “Warrant”), to subscribe for and purchase from Nutanix, Inc., a Delaware corporation with principal offices at 2350 Mission College Blvd, Suite 215, Santa Clara, CA 95054 (the
“Company”), that number of the fully paid and nonassessable Shares (as defined below) that can be purchased with
[                    ] Dollars ($[            ]) (the “Aggregate
Coverage Amount,” which amount represents 4% of the principal amount of that certain Convertible Promissory Note issued by the Company to the Holder as of the date hereof (the “Note”)) at the applicable Exercise Price set
forth below, subject to the provisions and upon the terms and conditions hereinafter set forth, which Aggregate Coverage Amount shall increase automatically with respect to each full month occurring ninety (90) days after the date hereof by an
amount equal to [                    ] Dollars ($[            ]), for as
long as the Note remains outstanding (collectively, with the Aggregate Coverage Amount, the “Maximum Aggregate Coverage Amount”, provided that the Maximum Aggregate Coverage Amount shall not exceed
[                    ] Dollars ($[            ]). For the purposes hereof,
the shares of the Company’s capital stock (the “Shares”) that may be purchased upon exercise of this Warrant in the manner described in Section 1(a) below or the conversion of the value of this Warrant in the manner
described in Section 1(b) below shall be at the Holder’s option, and the exercise price (the “Exercise Price”) per Share with respect to such exercise shall be as follows: (i) upon or at any time following a Financing
Event or a Non-Qualifying Financing (each as defined in the Note), shares of the preferred stock that are issued by the Company to the investors participating in such Financing Event or Non-Qualifying Financing (“Financing
Securities”), at an exercise price per Share equal to the Financing Price (as defined in the Note, and subject to adjustment as provided below); or (ii) in the event an Acquisition (as defined herein) takes place prior to a Financing
Event or a Non-Qualifying Financing, immediately prior to such Acquisition, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an exercise price per Share equal to the lower of:
(i) 80% of the amount of proceeds payable in respect of one share of Common Stock in the Acquisition (including, for purposes of such calculation, all outstanding options and warrants to purchase equity securities of the Company but
specifically excluding this Warrant 

 
and all other like Warrants issued pursuant to the Blumberg Convertible Note Financing (as defined below)), assuming for such calculation that the aggregate amount of proceeds paid to the Company
(or to the Company’s stockholders, as applicable) in the Acquisition was $10,000,000 and (ii) 80% of the amount of proceeds payable in respect of one share of Common Stock in the Acquisition (including, for purposes of such calculation,
all outstanding options and warrants to purchase equity securities of the Company but specifically excluding this Warrant and all other like Warrants issued pursuant to the Blumberg Convertible Note Financing)) (the applicable Exercise Price for the
Common Stock being referred to as the “Common Stock Exercise Price”). For purposes of this Warrant, “Blumberg Convertible Note Financing” means the convertible note loan financing led by Blumberg Capital II, L.P.
pursuant to which the Company is to receive loans of up to One Million Five Hundred Thousand Dollars ($1,500,000). 
 1. Method of
Exercise; Payment. 
 (a) Cash Exercise. The purchase rights represented by this Warrant may be exercised by the Holder, in whole
or in part, from time to time on or after the date hereof and until 5:00 p.m. PDT on the date that is ten (10) years from the date of this Warrant (the “Expiration Date”) by: (i) the surrender of this Warrant (with the
notice of exercise form (the “Notice of Exercise”) attached hereto as Exhibit A duly executed) at the principal office of the Company; and (ii) by the payment to the Company of an amount equal to the applicable Exercise
Price multiplied by the number of the applicable type of Shares being purchased, which amount may be paid, at the election of the Holder, by (x) wire transfer or certified check payable to the order of the Company, (y) the surrender by the
Holder to the Company of any promissory notes or other obligations issued by the Company, with all such notes and obligations so surrendered being credited against the Exercise Price in an amount equal to the principal amount thereof plus accrued
interest to the date of surrender or (z) a combination of the foregoing. The person or persons in whose name(s) any certificate(s) representing Shares shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s)
of record of, and shall be treated for all purposes as the record holder(s) of, the Shares represented thereby (and such Shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this
Warrant is exercised. 
 (b) Net Issue Exercise. In lieu of exercising this Warrant pursuant to Section 1(a) hereof, the Holder
may elect, in whole or in part, from time to time, on or after the date hereof and until 5:00 p.m. PDT on the Expiration Date to convert and to receive a number of Shares equal to the value (as determined below) of this Warrant (or the portion
thereof being canceled) by surrender of this Warrant at the principal office of the Company, together with a Notice of Exercise pursuant to which the provisions of this Section 1(b) are elected, such notice to expressly indicate both the
applicable type of Shares to be issued upon such conversion, the applicable Exercise Price per Share, and the portion (or whether all) of this Warrant, as measured by the Maximum Aggregate Coverage Amount, is to be applied to such conversion. In
such event, the Company shall issue to the Holder a number of Shares computed using the following formula: 
  

			
	 X = Y (A-B)
		
	       A
		

 Where X = the number of the applicable type of Shares to be issued to the Holder. 

  
 2 

 Y = the number of the applicable type of Shares that the indicated portion of the Maximum
Aggregate Coverage Amount of this Warrant could purchase at the applicable Exercise Price. 
 A = the fair market value of one Share, as
applicable, determined pursuant to Section 1(c) below. 
 B = the applicable Exercise Price per Share (as adjusted to the date of such
calculation) for the applicable type of Shares. 
 If this Warrant has not been exercised prior to the Expiration Date, this Warrant shall
be deemed to have been automatically exercised on the Expiration Date by net issue election pursuant to this Section 1(b) for the applicable type of Shares and based upon an applicable deemed Exercise Price per Share as follows:
(i) following a Financing Event or a Non-Qualifying Financing, for shares of the Financing Securities at the Financing Price; and (ii) for shares of Common Stock at the Common Stock Exercise Price. 

(c) Fair Market Value. For purposes of this Section 1, the fair market value of the Shares shall mean: 

(i) if the Shares are traded on a national securities exchange, the average of the closing price each day over the ten (10) trading day
period prior to the surrender of this Warrant for exercise in accordance with the terms hereof; 
 (ii) if the Shares are actively traded
over-the counter, the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) each day over the ten (10) trading day period prior to the surrender of this Warrant for exercise in accordance with the terms
hereof; or 
 (iii) if at any time the Shares are not listed on any national securities exchange or quoted in the NASDAQ system or the
over-the-counter market, then as determined by the board of directors of the Company in good faith. The foregoing notwithstanding, if Holder advises the board of directors in writing that Holder disagrees with such determination, then the Company
and Holder shall promptly agree upon a reputable investment banking firm to undertake such valuation, and the determination of such investment banking firm shall be binding upon the parties. If the parties cannot agree on an investment banking firm,
each party shall choose one investment banking firm and the two firms so chosen shall choose a third investment banking firm, which third firm shall conduct the valuation. If the valuation of such investment banking firm is more than five percent
(5%) greater than the value determined by the board of directors, then all fees and expenses of such investment banking firm shall be paid by the Company. In all other circumstances, such fees and expenses shall be paid one-half by Holder and
one-half by the Company. Neither the board of directors nor the investment banking firm shall take into consideration any discounts in determining fair market value, including, without limitation, any discount for minority interest or lack of
marketability. 
 (d) Stock Certificates. In the event of any exercise of the rights represented by this Warrant (whether pursuant to
Section 1(a) or 1(b)), certificates for the Shares so purchased shall be delivered to the Holder and, unless this Warrant has been fully exercised, a new Warrant representing the Shares with respect to which this Warrant shall not have been
exercised shall also be issued to the Holder within such time. 

  
 3 

 2. Stock Fully Paid; Reservation of Shares. All of the Shares issuable upon the exercise
of the rights represented by this Warrant will, upon issuance and receipt of the Exercise Price therefor, be fully paid and nonassessable, and free from all preemptive rights, rights of first refusal or first offer, taxes, liens and charges with
respect to the issuance thereof. In the event of a Financing Event or a Non-Qualifying Financing, in which the Company amends its Certificate of Incorporation in order to create authorized shares of the Financing Securities, the Company covenants
that it shall take all corporate action (including the solicitation of any consents or other approvals from the Company’s Board of Directors and stockholders) to make available out of its authorized but unissued shares of Financing Securities
(and, if applicable, its authorized but unissued shares of Common Stock, issuable upon conversion of the Financing Securities) solely for the purpose of issuing upon exercise or conversion of this Warrant as provided herein such number of shares of
the Financing Securities (and, if applicable, shares of Common Stock issuable upon conversion of the Financing Securities) as shall then be issuable upon the exercise or conversion of this Warrant. 

3. Adjustment of Exercise Price and Number of Shares. The number and kind of Shares purchasable upon the exercise of this Warrant and
the Exercise Price therefore shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
 (a)
Stock Splits, Dividends and Combinations. In the event that the Company shall at any time subdivide the outstanding Shares or shall issue a stock dividend on its outstanding Shares, the number of Shares issuable upon exercise of this Warrant
immediately prior to such subdivision or issuance of such stock dividend shall be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the Company shall at any time combine the outstanding
Shares, the number of Shares issuable upon exercise of this Warrant immediately prior to such combination shall be proportionately decreased, and the Exercise Price shall be proportionately increased, effective at the close of business on the date
of such subdivision, stock dividend or combination, as the case may be. 
 (b) Recapitalizations. If at any time or from time to time
there shall be a recapitalization of the Shares (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this Section 3), provision shall be made so that the Holder of this Warrant will thereafter
be entitled to receive upon exercise of this Warrant the number of shares of stock or other securities or property of the Company to which a holder of Shares would have been entitled on such recapitalization. In any such case, appropriate adjustment
shall be made in the application of the provisions of this Section 3 with respect to the rights of the Holder of this Warrant after the recapitalization to the end that the provisions of this Section 3 (including adjustment of the Exercise
Price then in effect and the number of Shares issuable upon exercise of this Warrant) shall be applicable after that event in as nearly an equivalent manner as may be practicable. 

(c) Acquisitions. Upon the closing of any Acquisition, unless this Warrant has otherwise been purchased by the successor entity from
the Holder, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the

  
 4 

 
unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Exercise Price shall be adjusted accordingly. As used
herein, “Acquisition” means any sale, license, or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation, or merger of the Company in which the holders of the Company’s
voting securities before the transaction (for such purpose treating all outstanding options and warrants to purchase voting securities of the Company as having been exercised and treating all outstanding debt and equity securities convertible into
voting securities of the Company as having been converted) beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction. 

(d) Notices. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable upon the
exercise of this Warrant in accordance with this Section 3, then, and in each such case, the Company shall give written notice thereof to the Holder at the address of such Holder as shown on the books of the Company, which notice shall state
the Exercise Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation of each. Any written notice by the Company
required or permitted hereunder shall be given by hand delivery or first class mail, postage prepaid, addressed to the Holder at the address shown on the books of the Company for the Holder. 

(e) Anti-dilution Adjustments to Preferred Stock. The parties hereto acknowledge and agree that, for the avoidance of doubt, with
respect to the Shares issuable upon the exercise of this Warrant, the Holder shall be entitled to the benefit of all adjustments to the conversion price of the applicable series of the Company’s preferred stock that may constitute the Shares as
may be set forth in the Company’s Certificate of Incorporation that shall have occurred since the date of filing of such Certificate of Incorporation (the “Certificate Filing Date”). Upon the exercise or conversion of this
Warrant, the conversion price of any preferred stock of the Company that may constitute the Shares shall be the applicable conversion price of such series of preferred stock as so adjusted since the Certificate Filing Date. 

4. Fractional Shares. No fractional Shares will be issued in connection with any exercise or conversion of this Warrant, but in lieu of
such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 5. Rights
of Stockholders. Nothing contained herein shall confer upon the Holder any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or
to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to
receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have been issued. 

6. Compliance with Securities Laws. By acceptance of this Warrant, the Holder acknowledges, represents and warrants to the Company that
(a) it is acquiring this Warrant (and the Shares issuable upon exercise of this Warrant, and the securities issuable, directly or indirectly, upon conversion of the Shares, if any; collectively referred to as the “Securities”)
for investment for such Holder’s own account, and not as a nominee or agent, and not with a view to 

  
 5 

 
the resale or distribution of any part hereof; and Holder has not been organized for the purpose of acquiring any of the Securities (or if Holder was organized for the purpose of acquiring any of
the Securities, all of its equity owners are accredited investors within the meaning of Rule 501(a) of Regulation D of the Securities Act of 1933, as amended); (b) Holder is an “accredited investor” within the meaning of
Rule 501(a) of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), as presently in effect; and (c) Holder is a resident of, or has a principal place of business in, the State indicated in
the space provided in the signature page hereof. Neither this Warrant nor any of the other Securities issuable upon exercise of this Warrant (and directly or indirectly, upon conversion of the Shares, if any) may be transferred or assigned in whole
or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. Subject to the provisions of this Section, this Warrant and all rights hereunder are transferable, in whole or in part, by Holder.

 7. Representations, Warranties and Covenants of the Company. 

(a) Representations and Warranties. The Company hereby represents and warrants to the Holder as follows: 

(i) The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company hereunder have been duly
authorized by all necessary corporate action on the part of the Company, and this Warrant is not inconsistent with the Company’s Certificate of Incorporation or Bylaws, and do not contravene any law or governmental rule, regulation or order
applicable to it, do not and will not contravene any provision of, or constitute a default under, any material indenture, mortgage, contract or other instrument to which it is a party or by which it is bound, and this Warrant constitutes a legal,
valid and binding agreement of the Company, enforceable in accordance with its terms, provided that Holder acknowledges that the Company has not yet created, designated or authorized any shares of Financing Securities for issuance by the Company as
of the date hereof, and would be required to take certain corporate actions, as contemplated in the affirmative covenant under Section 2 above, in order to have authorized and available for issuance a sufficient number of shares of Financing
Securities in order for the Holder to exercise and or convert this Warrant as contemplated herein. 
 (ii) No consent or approval of,
giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency or other person is required with respect to the execution, delivery and performance by the Company of
its obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the Securities Act of 1933, as amended and any filing required by applicable state securities law, which filings will be effective by the time
required thereby. 
 (b) Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or
distribution upon its capital stock, whether in cash, property, stock or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional
shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of its capital stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license or convey all
or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (i) at least twenty (20) days’ prior written notice of

  
 6 

 
the date on which a record will be taken for such dividend, distribution or subscription rights (and specifying the date on which the holders of capital stock will be entitled thereto) or for
determining rights to vote, if any, in respect of the matters referred to in this Section 7(b); or (ii) if no such record date will be established for the matter, at least twenty (20) days’ prior written notice of the date on
which any reclassification, recapitalization, merger, consolidation, sale, lease, license, conveyance, liquidation, dissolution or winding up will take place (and specifying the date on which the holders of capital stock will be entitled to exchange
their stock for securities or other property deliverable upon the occurrence of such event). 
 (c) Reservation of Shares. The
Company covenants and agrees that it will at all times reserve and set apart and have, free from preemptive rights, a sufficient number of shares of authorized but unissued capital stock of the Company to provide for the issuance of the Shares (and
the securities issuable, directly or indirectly, upon conversion of the Shares, if any) upon the exercise or conversion of this Warrant, provided that the foregoing obligation shall only apply to any shares of Financing Securities upon and after the
closing of a Financing Event or a Non-Qualifying Financing. 
 8. Registration Rights and Other Rights. In the event the Holder
exercises or converts this Warrant, the Holder shall have, with respect to all Shares issuable upon exercise or conversion of this Warrant (including securities issuable, directly or indirectly, upon the conversion thereof) the same registration
rights, information rights, inspection rights, rights of first offer, rights of first refusal, co-sale rights and other rights conferred upon holders of the Financing Securities issued in the Financing Event or the Non-Qualifying Financing, as the
case may be, on a pari passu basis with such Financing Securities. 
 9. Miscellaneous. 

(a) This Warrant shall be governed by, and construed in accordance with, the laws of the State of California, without regard to principles of
conflict of laws. 
 (b) The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the
terms hereof. 
 (c) The terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns
of the Company or the Holder. 
 (d) This Warrant, the Convertible Note and Warrant Purchase Agreement dated as of December 21, 2009,
among the Company and the Investors parties thereto, as may be amended from time to time (the “Purchase Agreement”), and the Notes (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement
between the parties with regard to the subjects hereof and thereof. 
 (e) The Company shall not, by amendment of its certificate of
incorporation or through any other means, directly or indirectly (including but not limited to entering into any agreement with respect to its securities which is inconsistent with the rights granted to the Holder of this Warrant or otherwise
conflicts with the provisions hereof), avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as
may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment. 

  
 7 

 (f) Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, the Company, at its expense, will execute and deliver to the holder of record, in lieu thereof, a new Warrant of like date and tenor. 

(g) This Warrant is one of a series of warrants (the “Series Warrants”) for the purchase of shares of capital stock of the
Company issued by the Company in connection with the Purchase Agreement. 
 (h) No term of this Warrant, or any provision hereof, may be
amended or waived, except by the written consent of the holders of then outstanding Series Warrants representing at least a majority of the Maximum Aggregate Coverage Amount collectively represented by all of the then outstanding Series Warrants
(the “Requisite Holders”) and the Company. Notwithstanding the foregoing, no amendment or waiver of any term of this Warrant shall be effective unless such amendment and waiver shall apply in an equal and ratable manner to all of
the Series Warrants. 
 (i) The representations, warranties and covenants contained in this Warrant shall survive the exercise or conversion
of this Warrant, shall apply to the Shares issued upon exercise or conversion of this Warrant, and shall continue for as long as Holder owns any Shares (or any securities into which the Shares are convertible). 

(j) This Warrant may be executed in counterparts, each of which when so executed shall be deemed an original, but both of which when taken
together shall constitute one and the same instrument. 
 [SIGNATURE PAGE FOLLOWS] 

  
 8 

 IN WITNESS WHEREOF, each of the Company and the Holder has executed this Warrant as of the day and year first set
forth above. 
  

			
	COMPANY:
	
	NUTANIX, INC.
		
	By:		  

			Name:
			Title:
	
	HOLDER:
	
	  

	
	Address:

 EXHIBIT A 

NOTICE OF EXERCISE 
  

	TO:	Nutanix, Inc. 

	  	Attention: Chief Executive Officer 

 The undersigned holder of that certain Warrant to Purchase Shares of
Capital Stock (the “Warrant”) of Nutanix, Inc. (the “Company”) dated                  , 200    , hereby
elects to acquire the indicated shares of the Company’s capital stock (the “Shares”) under either Section 1(a) or Section 1(b) of the Warrant, as indicated below: 

1(a). The undersigned hereby elects to exercise the Warrant under Section 1(a) to purchase
                     (please leave blank if you choose alternative No. 1(b) below) shares of [Series
     Preferred Stock] [Common Stock] (please cross out the inapplicable class of capital stock) pursuant to the terms of the Warrant, and tenders herewith payment of the purchase price of such Shares in full at the
Exercise Price per Share equal to $            . 
 1(b). In lieu of
exercising the Warrant for cash or check, the undersigned hereby elects to effect the net issuance provision of Section 1(b) of the Warrant by converting $             of the
Maximum Aggregate Coverage Amount set forth on the first page of such Warrant to receive              (leave blank if you choose Alternative No. 1(a) above) shares of [Series
     Preferred Stock] [Common Stock] (please cross out the inapplicable class of capital stock) pursuant to the terms of the Warrant. (Initial here if the undersigned elects this
alternative).            . 
 2. Please issue a certificate or
certificates representing said Shares in the name of the undersigned or in such other name as is specified below: 
 The undersigned
acknowledges, represents and warrants to the Company that (a) it is acquiring the Shares (and the other securities issuable, directly or indirectly, if any, upon the conversion of the Shares) for investment for the undersigned’s own
account, and not as a nominee or agent, and not with a view to the resale or distribution of any part hereof; and the undersigned has not been organized for the purpose of acquiring the Shares or such other securities issuable hereunder; (b) it
is an “accredited investor” within the meaning of Rule 501(a) of Regulation D of the Securities Act of 1933, as amended, as presently in effect; and (c) it is a resident of, or has a principal place of business in, the State
at the address set forth below: 
  

	
	  

	(Name)
	  

	  

	(Address)
	

  

			
	By:		  

	Name:		  

	Title:		  

	Date:EX-4.4

 Exhibit 4.4 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (the “1933
ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 PLAIN ENGLISH WARRANT AGREEMENT 

This is a PLAIN ENGLISH WARRANT AGREEMENT dated December 12, 2013 by and between NUTANIX, INC., a Delaware corporation, and TRIPLEPOINT CAPITAL
LLC, a Delaware limited liability company. 
 The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT
CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is NUTANIX, INC., and not to any individual. The words “the Parties” refers to both TRIPLEPOINT CAPITAL LLC and NUTANIX, INC. This Plain English Warrant
Agreement may be referred to as the “Warrant Agreement”. 
 The Parties have entered into a Plain English Growth Capital Loan and Security
Agreement dated as of December 12, 2013, the “Loan Agreement”. 
 In consideration of such Loan Agreement, the Parties agree to the following
mutual agreements and conditions set forth below: 
  

							
	 WARRANT INFORMATION

 

	 Effective Date
	  	 Warrant Number
	  	 Loan Facility Number

	 December 12, 2013
	  	0839-W-01	  	
				
	 Warrant Coverage
	  	 Number of Shares
	  	 Price Per Share
	  	 Type of Stock

	 n/a

 
	  	 45,000
  
	  	 $7.2885
  
	  	 Series D Preferred Stock

 

  

					
	
	 OUR CONTACT INFORMATION

 

	 Name
	  	 Address For Notices
	  	 Contact Person

	 TriplePoint Capital LLC
	  	 2755 Sand Hill Road, Ste. 150

Menlo Park, CA 94025
	  	         Sajal Srivastava, COO

	
	 YOUR CONTACT INFORMATION

 

	 Customer Name
	  	 Address For Notices
	  	 Contact Person

	 Nutanix, Inc.
	  	 1740 Technology Drive

Suite 150
 San Jose, CA
95110
	  	 Name: Kenneth Long, VP of Accounting

  
 1 

	1.	WHAT YOU AGREE TO GRANT US 

 You grant to Us and We are entitled, upon the terms and subject to the
conditions set forth in this Warrant Agreement, to purchase from You Forty-Five Thousand (45,000) fully paid and non-assessable shares of Your Warrant Stock at a purchase price equal to per share equal to the Exercise Price. 

The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4 hereof. 

For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below: 

“Exercise Price” means $7.2885. 

“Warrant Stock” means Your Series D Preferred Stock. 

The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price of the
investment will be allocable to the Warrant Agreement and the balance shall be allocable to the Loan Agreement for income tax purposes and the original issue discount on the Loan Agreement shall be considered to be zero. 

 

	2.	WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK. 

 The term of this Warrant Agreement and Our right
to purchase Warrant Stock will begin the Effective Date, and shall be available through and including December 12, 2020. 
 Notwithstanding the
foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a
Person that is not one of Your affiliates, in which Your common stock is exchanged for cash and/or stock that is traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the
consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) stock that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or
greater than two (2) times the aggregate Exercise Price (as adjusted) or (ii) cash. No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together
with a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of
the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning
Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably necessary to an informed evaluation of Our rights under this Agreement. 

 

	3.	HOW WE MAY PURCHASE YOUR WARRANT STOCK. 

 We may exercise Our purchase rights, in whole or in part, at
any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I. Promptly upon receipt of the Notice of Exercise
and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant
Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any. 

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net
Issuance method, You will issue Warrant Stock using the following formula: 
  

					
					X = Y(A-B)
					     A

			 Where: X =
		the number of shares of Warrant Stock to be issued to Us.
			Y =		the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.
			A =		the fair market value of one share of Warrant Stock.
			B =		the Exercise Price.

  
 2 

 For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each
share of Warrant Stock: 
 If the exercise is in connection with the initial public offering of Your Common Stock, and if Your registration statement
relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and (y) the
number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; 
 If this Warrant Agreement is
exercised after, and not in connection with Your initial public offering, and: 
  

	•	 	if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair
market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; or 

 

	•	 	if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day
period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such
exercise. 

 If this Warrant Agreement is exercised prior to or after Your initial public offering, and: 

 

	•	 	Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market
value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold, from authorized but unissued shares), as determined in good faith by
Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to
which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other
consolidation. 

 During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and
reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock. 

If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that
are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement. 
 If at
the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date,
then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You
shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us. 
  

	4.	WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE. 

  

	•	 	 If You are Acquired. Subject to termination as set forth in Section 2, if at any time: (i) there is a reorganization of Your stock
(other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell
or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to 

  
 3 

	 	 
any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of
the capital stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to receive, upon exercise of Our
rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our
rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by Your Board of Directors) shall be made in the application of the provisions of this Warrant Agreement
with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest
extent possible. 

  

	•	 	If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the securities as to which purchase rights under this Warrant Agreement
exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change
with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 

 

	•	 	If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Warrant Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased
in the case of a combination. 

  

	•	 	If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically provided for in the above paragraphs) of Your Warrant Stock, then the
Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of
which shall be the total number of all shares of Your Warrant Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of all shares of Your Warrant Stock outstanding
immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying
the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from
such adjustment. 

  

	•	 	If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock. All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set
forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with
written notice of any issuance of Your stock or other equity security to occur after the Effective Date (other than issuances of stock or equity securities pursuant to customary employee stock plans), which notice shall include (a) the price at
which such stock or security was or is to be sold, (b) the number of shares issued or to be issued, and (c) such other information as necessary for Us to determine if a dilutive event has occurred or will occur as a result of such
issuance. 

  

	5.	WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT. 

 Subject to the terms and conditions contained in
Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and all its rights. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit
III, and Our payment of all transfer taxes and other governmental charges involved in such transfer. 
  

	6.	REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU. 

  

	•	 	 Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly
reserved and when issued in accordance with the provisions of this Warrant 

  
 4 

	 	 
Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however, that the Warrant Stock
issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other
cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any
certificate in a name other than TriplePoint Capital LLC. 

  

	•	 	Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been
duly authorized by all necessary corporate action on Your part and this Warrant Agreement is not inconsistent with Your Certificate of Incorporation or Bylaws, does not contravene any law or governmental rule, regulation or order applicable to it,
do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes a legal, valid and
binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance,
injunctive relief and other equitable remedies. 

  

	•	 	Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency is required with
respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and state securities laws, which filings will be effective by the times required
thereby. 

  

	•	 	Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized and validly issued and are fully paid and nonassessable. All
outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date: 

Your authorized capital consists of (A) 135,000,000 shares of Common Stock, of which 41,478,013 shares of Common Stock are issued and outstanding,
(B) 28,165,300 shares of Series A Preferred Stock, of which 27,396,198 shares are issued and outstanding, (C) 16,558,441 shares of Series B Preferred Stock, all of which are issued and outstanding, (D) 7,683,710 shares of Series C
Preferred Stock, all of which are issued and outstanding, and (E) 13,957,445 shares of Series D Preferred Stock, of which 10,976,189 shares are issued and outstanding. 

You have reserved 32,465,594 shares of Common Stock for issuance under Your Stock Incentive Plans, under which 10,736,041 options have been granted and
commitments to issue an additional 4,753,417 in options have been made. Warrants to purchase a total of 769,102 shares of Series A Preferred Stock and 10,000 shares of Series D Preferred Stock are also outstanding. Except as otherwise provided in
this Warrant Agreement and as noted above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of Your capital stock or other of Your
securities. 
 Except as set forth in Your Investors’ Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to
the issuance of this Warrant, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock. 
  

	•	 	Other Commitments to Register Securities. Except as set forth in this Warrant Agreement and the Investors’ Rights Agreement, You are not, pursuant to the terms of any other agreement currently in existence,
under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued. 

  

	•	 	Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt from
(i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

  
 5 

	•	 	Compliance with Rule 144. We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. 

 

	•	 	No Impairment. You agree not to, by amendment of Your Certificate of Incorporation, by-laws or other organizational or charter documents or through a reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in
carrying out of all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment. However, You shall not be deemed to have impaired Our rights if You
amend Your Certificate of Incorporation, or the holders of Your preferred stock waive their rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such
amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock; provided, however, that, notwithstanding the
foregoing, You shall not impose any restrictions on the transferability or alienability of the Warrant Stock other than in effect as of the Effective Date without the express written consent of Us. 

 

	7.	OUR REPRESENTATIONS AND COVENANTS TO YOU. 

  

	•	 	Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment
purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation of the 1933 Act. 

 

	•	 	Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not
registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that
Your reliance on such exemption is predicated on the representations set forth in this Section 7. 

  

	•	 	Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion
of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and
(iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption
from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights
or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any
particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without
registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to You at Our request by such
Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter
or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as
to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933
Act registration or exemption. 

  

	•	 	Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our
investment, and have the ability to bear the economic risks of Our investment. 

  

	•	 	 Risk of No Registration. We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of
the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or 

  
 6 

	 	 
if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or
(ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that
any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and
conditions of that Rule. 

  

	•	 	Accredited Investor. We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect. 

 

	8.	NOTICES YOU AGREE TO PROVIDE US. 

 Subject to applicable law and Your confidentiality obligations to
third parties, You agree to give Us at least ten (10) days prior written notice of the following events: 
  

	•	 	If You pay a Dividend or distribution declaration upon Your stock. 

  

	•	 	If You offer for subscription pro-rata to the existing shareholders additional stock or other rights. 

  

	•	 	If You consummate or sign definitive documents providing for a Merger Event. 

  

	•	 	If You have an initial public offering. 

  

	•	 	If You dissolve or liquidate. 

 All notices in this Section must set forth details of the event, how the
event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment. 
 Timely Notice. Your failure to timely
provide such notice required above shall entitle Us to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Us. 

 

	9.	DOCUMENTS YOU WILL PROVIDE US. 

 Upon signing this Warrant Agreement You will provide Us with:

  

	•	 	Executed originals of this Warrant Agreement, and all other documents and instruments that We may reasonably require 

  

	•	 	Secretary’s certificate of incumbency and authority 

  

	•	 	Certified copy of resolutions of Your board of directors approving this Warrant Agreement 

  

	•	 	Certified copy of Certificate of Incorporation and by-laws as amended through the Effective Date 

  

	•	 	Current Investors’ Rights Agreement 

 So long as this Warrant Agreement is in effect, You shall
provide Us with the following: 
  

	•	 	Promptly after the closing of any equity financing, or extension of an existing round of equity financing, occurring after the Effective Date, in which You issue preferred stock or other securities You will provide Us
with copies of the fully executed equity financing documents, including without limitation the related stock purchase agreement, investors rights agreement, voting agreement, amended or restated articles/certificates of incorporation, current
capitalization table and other related documents. 

  

	•	 	Promptly after completion, You shall provide Us with any 409A Valuation Reports or other similar reports prepared for You (but in no event later than two (2) Business Days after Our request). 

  
 7 

	•	 	After all obligations under the Loan Agreement have been finally paid in full, You will provide us with the financial statements and other reports described in Section 2.1 of the Investors’ Rights Agreement,
subject to the terms and conditions of the Investors’ Rights Agreement. 

  

	•	 	You shall submit to Us any other documents and other information that We may reasonably request from time to time and are necessary to implement the provisions and purposes of this Warrant Agreement. 

 

	•	 	We will keep all information You provide to Us under this Warrant Agreement confidential and We will use such information solely for purposes of (i) making an exercise decision under this Warrant Agreement, and
(ii) managing Our investment, if any, in Your Preferred Stock. 

  

	10.	REGISTRATION RIGHTS UNDER THE 1933 ACT. 

 The shares of Your common stock into which the Warrant Stock is
convertible shall have registration rights as set forth in the Investors’ Rights Agreement, dated as of August 20, 2012, (as amended, the “Investors’ Rights Agreement”). The provisions set forth in Your Investors’
Rights Agreement relating to such registration rights in effect as of the date of this Warrant Agreement may not be amended, modified or waived without Our prior written consent unless such amendment, modification or waiver affects the rights
associated with the shares of common stock into which the Warrant Stock is convertible in the same manner as such amendment, modification, or waiver affects the rights associated with all other shares of the same series and class of stock as the
Warrant Stock. 
  

	11.	OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY. 

 Effective Date. This Warrant Agreement shall
be construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties. 

Attorney’s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party
shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement. 
 Governing Law.
This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws. 

Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or
federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State
of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably
agrees to be bound by any judgment rendered thereby in connection with this Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this Warrant Agreement shall be effective if given in accordance with
the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either
party to bring proceedings in the courts of any other jurisdiction. 
 Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in
connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that
their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM
(COLLECTIVELY, “CLAIMS”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR
FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A
RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE 

  
 8 

 
APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP
REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE
APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve persons other than You and Us; Claims
that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement. 

Counterparts. This Warrant Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 Notices. Any notice required or permitted under this Warrant Agreement shall be given in writing and
shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized
courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party. 

Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or
by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be
readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Warrant Agreement, the injured party shall be entitled
to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Warrant Agreement. 

Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall
survive the execution and delivery of this Warrant Agreement. 
 Severability. In the event any one or more of the provisions of this Warrant
Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid,
legal and enforceable provision, which comes closest to the intention of the Parties underlying the invalid, illegal or unenforceable provision. 

Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and
supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. 

Amendments. Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties. 

Lost Warrants or Stock Certificates. You covenant to Us that, upon receipt of evidence reasonably satisfactory to Us of the loss, theft, destruction or
mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation
of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate. 

  
 9 

 Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or receive
dividends or be deemed the holder of Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any of the rights of
one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant Agreement is exercised
and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
 Facsimile Signatures. This Warrant
Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

(Signature Page to Follow) 

  
 10 

 IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers
who are duly authorized as of the Effective Date. 
  

			
	You:		NUTANIX, INC.
		
	Signature:		 /s/ Kenneth Long

		
	Print Name:        		 Kenneth Long

		
	Title:		 Vice President of Accounting

		
	Us:		TRIPLEPOINT CAPITAL LLC
		
	Signature:		 /s/ Sajal Srivastava

		
	Print Name:		 Sajal Srivastava

		
	Title:		 COO

 [SIGNATURE PAGE TO WARRANT AGREEMENT] 

  
 11 

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	[                            ] 

 

	1.	We hereby elect to purchase [            ] shares of the Series
[            ] Preferred Stock of [            ], pursuant to the terms of the Plain English Warrant
Agreement dated the [            ] day of [            ],
[20    ] (the “Plain English Warrant Agreement”) between You and Us, We hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.

  

	2.	Method of Exercise (Please initial the applicable blank) 

  

	 	a.	             The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the
purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

  

	 	b.	             The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of
the Plain English Warrant Agreement. 

  

	3.	In exercising Our rights to purchase the Series [            ] Preferred Stock of
[                    ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in
Section 7 of the Plain English Warrant Agreement. 

 Please issue a certificate or certificates representing these purchased shares of
Series [            ] Preferred Stock in Our name or in such other name as is specified below. 
  

					
		 	  

		 	(Name)
		
		 	  

		 	(Address)
			
		 	US:	 	TRIPLEPOINT CAPITAL LLC
			
		 	 By:
	 	  

			
		 	 Title:
	 	  

			
		 	 Date:
	 	  

  
 12 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 Nutanix,
Inc., hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [            ] shares of the Series
[            ] Preferred Stock of [                    ],
pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Plain
English Warrant Agreement. 
  

							
	 YOU:
	 	NUTANIX, INC.	 	
				
		 	By:	 	
                  
                                         
                  
	 	
				
		 	Title:	 	  
	 	
				
		 	Date:	 	  
	 	

  
 13 

 EXHIBIT III 

TRANSFER NOTICE 
 RE: Plain English
Warrant Agreement between Nutanix, Inc. and Triplepoint Capital LLC dated November     , 2013 
 FOR VALUE RECEIVED,
the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

					
	  
				
	 (Please Print)
				

					
			
	 Whose address is
		  
		
		
	  
		

					
			
	Dated:		  
		
			
	Holder’s Signature:		  
		
			
	Holder’s Address:		  
		
			
	Transferee’s Signature:		  
		
			
	Transferee’s Address:		  
		
			
	Signature Guaranteed:		  
		

 Transferee hereby agrees to be bound by the terms of the Warrant Agreement and hereby makes the representations and
covenants set forth in Section 7 to Nutanix, Inc. 
 NOTE: The signature to this Transfer Notice must correspond with the name as it appears
on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to
assign the foregoing Plain English Warrant Agreement. 

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]